source
- Kardigan plans $320M IPO for heart drugs as Nasdaq listings gain steamParabilis Medicines' record-breaking IPO will be a tough act to follow, but a drug developer with three late-stage cardio medicines is up for the challenge. It's led by a CEO who sold ...Endpoints · 2mo ago↗ source
- J&J looks to widen Imaavy’s use; $300M backs rare disease drug launchNew data suggest Imaavy could be an effective treatment for autoimmune anemia. Elsewhere, Enliven detailed data for a Merck leukemia rival and MBX hyperparathyroidism drug hit its goal.BioPharma Dive · 2mo ago↗ source
- STAT+: Pharmalittle: We’re reading about employer coverage of obesity drugs, another Sanofi setback, and moreMore employers are planning to drop coverage of GLP-1 drugs for weight loss next year as increasing numbers of people take the medications